Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

enliGHten: A Multicenter, Phase 3, Long-Term, Open-Label Trial Investigating Safety and Efficacy of TransCon hGH Administered Once-Weekly in Children With Growth Hormone Deficiency (GHD) Who Have Completed a Prior TransCon hGH Clinical Trial

NCT03344458 is registered in ClinicalTrials.gov with Ascendis Pharma A/S as lead sponsor.

NCT NCT03344458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03344458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
enliGHten: A Multicenter, Phase 3, Long-Term, Open-Label Trial Investigating Safety and Efficacy of TransCon hGH Administered Once-Weekly in Children With Growth Hormone Deficiency (GHD) Who Have Completed a Prior TransCon hGH Clinical Trial
Lead sponsor
Ascendis Pharma A/S
Phase
Phase 3
Overall status
Completed
Start date
December 19, 2017
Completion date
February 21, 2023
Enrollment
298 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

endocrine system diseases, growth hormone deficiency, pediatric, hormone deficiency, pituitary diseases